Invitrocue Competitors and Similar CompaniesClear all
Invitrocue's competitors and similar companies include Epsilogen, Artiva Biotherapeutics and Viracta Therapeutics.
 Invitrocue Invitrocue is a life sciences company that specializes in developing 3D cell-based models derived from liver and tumour tissues. |  Epsilogen Epsilogen (formerly IGEM Therapeutics) is an immuno-oncology company specializing in the development of IgE antibody drugs to fight cancer.
|  Artiva Biotherapeutics Artiva Biotherapeutics is a company that develops off-the-shelf cell therapies designed to treat hematologic malignancies or solid tumors. |  Viracta Therapeutics Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases. | |
Founding Date | Founding Date 2012 | Founding Date 2017 | Founding Date 2019 | Founding Date 2016 |
Type | Type Public | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations Singapore, SG HQ Sydney, AU Su Zhou Shi, CN München, DE Madrid, ES | Locations Reading, GB HQ London, GB | Locations San Diego, US HQ | Locations Encinitas, US HQ |
Employees | Employees N/A | Employees 28 | Employees 81 | Employees 323% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 263.8 m | Valuation ($) 8.7 m |
Financial | ||||
Net income | Net income ($6.7m) (FY, 2019) | Net income N/A | Net income ($83.9m) (FY, 2025) | Net income ($51.1m) (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 78m | Total funding raised $ 18.4m |
For sources of this data, please see the company profile
View Company Profiles
Epsilogen
HQ
Reading, GB
Employees
28
Epsilogen (formerly IGEM Therapeutics) is an immuno-oncology company specializing in the development of IgE antibody drugs to fight cancer.
View companyArtiva Biotherapeutics
HQ
San Diego, US
Employees
81
Artiva Biotherapeutics is a company that develops off-the-shelf cell therapies designed to treat hematologic malignancies or solid tumors.
View companyViracta Therapeutics
HQ
Encinitas, US
Employees
32↑ 3% increase
Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases.
View company